IMR Press / FBE / Volume 5 / Issue 3 / DOI: 10.2741/E676

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Prevention of cancer and inflammation by soybean protease inhibitors

Show Less
1 Department of Obstetrics and Gynecology, Nara Medical University, Nara, Japan

*Author to whom correspondence should be addressed.

Front. Biosci. (Elite Ed) 2013, 5(3), 966–973; https://doi.org/10.2741/E676
Published: 1 June 2013
Abstract

Several plant-based nutrients and non-nutrients that can inhibit mutagenesis and cell proliferation have been identified. Some of the most promising compounds identified as chemopreventive and anti-metastatic agents include soybean-derived protease inhibitors (PIs), Bowman-Birk Inhibitor (BBI) and Kunitz-Trypsin Inhibitor (KTI). A growing body of evidence suggests that BBI could act as anticarcinogenic agent and KTI is considered to prevent cancer invasion and metastasis. These inhibitors are non-toxic, are of low cost and can be taken orally or as a part of the daily diet. PIs are undergoing investigation in the clinical setting as potential agents for chemoprevention and anti-metastasis. A complex scenario about the interaction between PIs and cell signaling has been emerging. Soybean PIs are not just antiproteolytic proteins, but can also be modulators of cell signal transduction. Cancer and inflammatory treatment strategies modulating signal transduction need further investigation.

Keywords
Bowman-Birk Inhibitor
Kunitz-Trypsin Inhibitor
Nutraceuticals
Soybean
Cancer
Inflammation
Review
Share
Back to top